1
|
Fung WWS, Chao ACW, Pang WF, Wong RSM, Chow KM, Szeto CC. An unusual case of adult-onset still's disease complicated with anti-complement factor H antibodies associated atypical haemolytic uraemic syndrome. BMC Nephrol 2024; 25:164. [PMID: 38745129 PMCID: PMC11094913 DOI: 10.1186/s12882-024-03548-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Accepted: 03/15/2024] [Indexed: 05/16/2024] Open
Abstract
BACKGROUND Atypical haemolytic uremic syndrome (aHUS) is an uncommon form of thrombotic microangiopathy (TMA). However, it remains difficult to diagnose the disease early, given its non-specific and overlapping presentation to other conditions such as thrombotic thrombocytopenic purpura and typical HUS. It is also important to identify the underlying causes and to distinguish between primary (due to a genetic abnormality leading to a dysregulated alternative complement pathway) and secondary (often attributed by severe infection or inflammation) forms of the disease, as there is now effective treatment such as monoclonal antibodies against C5 for primary aHUS. However, primary aHUS with severe inflammation are often mistaken as a secondary HUS. We presented an unusual case of adult-onset Still's disease (AOSD) with macrophage activation syndrome (MAS), which is in fact associated with anti-complement factor H (anti-CFH) antibodies related aHUS. Although the aHUS may be triggered by the severe inflammation from the AOSD, the presence of anti-CFH antibodies suggests an underlying genetic defect in the alternative complement pathway, predisposing to primary aHUS. One should note that anti-CFH antibodies associated aHUS may not always associate with genetic predisposition to complement dysregulation and can be an autoimmune form of aHUS, highlighting the importance of genetic testing. CASE PRESENTATION A 42 years old man was admitted with suspected adult-onset Still's disease. Intravenous methylprednisolone was started but patient was complicated with acute encephalopathy and low platelet. ADAMTS13 test returned to be normal and concurrent aHUS was eventually suspected, 26 days after the initial thrombocytopenia was presented. Plasma exchange was started and patient eventually had 2 doses of eculizumab after funding was approved. Concurrent tocilizumab was also used to treat the adult-onset Still's disease with MAS. The patient was eventually stabilised and long-term tocilizumab maintenance treatment was planned instead of eculizumab following haematology review. Although the aHUS may be a secondary event to MAS according to haematology opinion and the genetic test came back negative for the five major aHUS gene, high titre of anti-CFH antibodies was detected (1242 AU/ml). CONCLUSION Our case highlighted the importance of prompt anti-CFH antibodies test and genetic testing for aHUS in patients with severe AOSD and features of TMA. Our case also emphasized testing for structural variants within the CFH and CFH-related proteins gene region, as part of the routine genetic analysis in patients with anti-CFH antibodies associated aHUS to improve diagnostic approaches.
Collapse
Affiliation(s)
- Winston Wing-Shing Fung
- Division of Nephrology, Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong, China.
- Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China.
| | - Amelia Chien-Wei Chao
- Division of Nephrology, Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong, China
- Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China
| | - Wing-Fai Pang
- Division of Nephrology, Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong, China
- Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China
| | - Raymond Siu-Ming Wong
- Division of Haematology, Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong, China
- Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China
| | - Kai-Ming Chow
- Division of Nephrology, Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong, China
- Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China
| | - Cheuk-Chun Szeto
- Division of Nephrology, Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong, China
- Li Ka Shing Institute of Health Sciences (LiHS), The Chinese University of Hong Kong, Shatin, Hong Kong, China
- Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China
| |
Collapse
|
2
|
Angchaisuksiri P, Amurao-Abiera M, Chou SC, Chewcharat P, Chozie NA, Gomez R, Leng TS, Lin PC, Mai NT, Muda Z, Seth T, Sosothikul D, Siu-Ming Wong R. Haemophilia care in Asia: Learning from clinical practice in some Asian countries. Haemophilia 2024; 30:609-616. [PMID: 38523289 DOI: 10.1111/hae.14998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 01/29/2024] [Accepted: 02/13/2024] [Indexed: 03/26/2024]
Abstract
BACKGROUND The healthcare systems in Asia vary greatly due to the socio-economic and cultural diversities which impact haemophilia management. METHODS An advisory board meeting was conducted with experts in haemophilia care from Asia to understand the heterogeneity in clinical practices and care provision in the region. FINDINGS The overall prevalence of haemophilia in Asia ranges between 3 and 8.58/100,000 patients. Haemophilia A was more prevalent as compared to haemophilia B with a ratio of around 5:1. There is under-diagnosis in the region due to lack of diagnosis, registries and/or lack of appropriate facilities in suburban areas. Most patients are referred to the haematologists by their families or primary care physicians, while some are identified during bleeding episodes. Genetic testing faces obstacles like resource constraints, services available at limited centres and unwillingness of patients to participate. Prophylaxis is offered for people with haemophilia (PWH) with a severe bleeding phenotype. Recombinant factors are approved in most countries across the region and are the preferred therapy. The challenges highlighted for not receiving a high standard of care include patients' reluctance to use an intravenous treatment, poor patient compliance due to frequency of infusions, budget constraints and lack of funding, insurance, availability and accessibility of factor concentrates. Prevalence of neutralizing antibodies ranged from 5% to 20% in the region. Use of immune tolerance induction and bypassing agents to treat inhibitors depends on their cost and availability. CONCLUSION Haemophilia care in Asia has evolved to a great extent. However, some challenges remain for which a strategic approach along with multi-stakeholder involvement are needed.
Collapse
Affiliation(s)
| | - Marilou Amurao-Abiera
- Philippine Children's Medical Center, Cancer and Hematology Division (Head), Quezon City, Philippines
| | - Sheng-Chien Chou
- Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | - Pol Chewcharat
- Medical Affairs Manager Pfizer Thailand, Bangkok, Thailand
| | - Novie Amelia Chozie
- Division of Hematology Oncology, Department of Child Health Science, Dr. Cipto Mangunkusumo Hospital/Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
| | - Roy Gomez
- Emerging Asia Cluster Medical Lead - Rare Disease, Pfizer Singapore, Singapore, Singapore
| | - Tien Sim Leng
- Director, Haemophilia Centre, Department of Haematology, Singapore General Hospital, Singapore, Singapore
| | - Pei-Chin Lin
- Division of Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital; Department of Pediatrics, School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Nguyen Thi Mai
- Hemophilia Centre, National Institute of Hematology and Blood Transfusion, Hanoi, Vietnam
| | - Zulaiha Muda
- Paediatric Haematology Oncology Unit, Hospital Tunku Azizah Women Children Hospital, Kuala Lumpur, Malaysia
| | - Tulika Seth
- Professor Hematology, AIIMS, New Delhi, India
| | - Darintr Sosothikul
- Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok and Integrative and Innovative Hematology/Oncology Research Unit, Faculty of Medicine, Chulalongkorn, Bangkok, Thailand
| | - Raymond Siu-Ming Wong
- Division of Haematology, Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
- Sir YK Pao Centre for Cancer, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| |
Collapse
|
3
|
Liam CCK, Tiao JYH, Yap YY, Lee YL, Sathar J, McRae S, Davis A, Curnow J, Bird R, Choi P, Angchaisuksiri P, Tien SL, Lam JCM, Oh D, Kim JS, Yoon SS, Wong RSM, Lauren C, Merriman EG, Enjeti A, Smith M, Baker RI. Validating lactate dehydrogenase (LDH) as a component of the PLASMIC predictive tool (PLASMIC-LDH). Blood Res 2023; 58:36-41. [PMID: 36632683 PMCID: PMC10063598 DOI: 10.5045/br.2023.2022133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Revised: 11/11/2022] [Accepted: 01/05/2023] [Indexed: 01/13/2023] Open
Abstract
Background The PLASMIC score is a convenient tool for predicting ADAMTS13 activity of <10%. Lactate dehydrogenase (LDH) is widely used as a marker of haemolysis in thrombotic thrombocytopenic purpura (TTP) monitoring, and could be used as a replacement marker for lysis. We aimed to validate the PLASMIC score in a multi-centre Asia Pacific region, and to explore whether LDH could be used as a replacement marker for lysis. Methods Records of patients with thrombotic microangiopathy (TMA) were reviewed. Patients' ADAMTS13 activity levels were obtained, along with clinical/laboratory findings relevant to the PLASMIC score. Both PLASMIC scores and PLASMIC-LDH scores, in which LDH replaced traditional lysis markers, were calculated. We generated a receiver operator characteristics (ROC) curve and compared the area under the curve values (AUC) to determine the predictive ability of each score. Results 46 patients fulfilled the inclusion criteria, of which 34 had ADAMTS13 activity levels of <10%. When the patients were divided into intermediate-to-high risk (scores 5-7) and low risk (scores 0-4), the PLASMIC score showed a sensitivity of 97.1% and specificity of 58.3%, with a positive predictive value (PPV) of 86.8% and negative predictive value (NPV) of 87.5%. The PLASMIC-LDH score had a sensitivity of 97.1% and specificity of 33.3%, with a PPV of 80.5% and NPV of 80.0%. Conclusion Our study validated the utility of the PLASMIC score, and demonstrated PLASMIC-LDH as a reasonable alternative in the absence of traditional lysis markers, to help identify high-risk patients for treatment via plasma exchange.
Collapse
Affiliation(s)
- Christopher Chin Keong Liam
- Perth Blood Institute, Perth, Australia.,Western Australia Centre of Thrombosis and Haemostasis (WACTH), Murdoch University, Perth, Australia.,Haematology, Hospital Ampang, Malaysia
| | - Jim Yu-Hsiang Tiao
- Perth Blood Institute, Perth, Australia.,Western Australia Centre of Thrombosis and Haemostasis (WACTH), Murdoch University, Perth, Australia
| | | | - Yi Lin Lee
- Centre for Clinical Trials, Hospital Ampang, Selangor, Malaysia
| | | | - Simon McRae
- Haematology, Northern Cancer Service, Tasmania, Australia
| | - Amanda Davis
- Haematology, The Alfred Hospital, Melbourne,Australia
| | | | - Robert Bird
- Haematology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
| | - Philip Choi
- Haematology, The Canberra Hospital, Canberra, Australia
| | - Pantep Angchaisuksiri
- Haematology and Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | | | | | - Doyeun Oh
- Internal Medicine, Cha Bundang Medical Centre, Cha University, Seongnam, Korea
| | - Jin Seok Kim
- Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
| | - Sung-Soo Yoon
- Internal Medicine, Seoul National University Hospital, Seoul, Korea
| | - Raymond Siu-Ming Wong
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong
| | - Carolyn Lauren
- Haematology, Canterbury District Health Board, Christchurch, Auckland, New Zealand
| | - Eileen Grace Merriman
- Haematology, North Shore Hospital, Auckland, New Zealand.,Haematology, Waitemata District Health Board, Auckland, New Zealand
| | - Anoop Enjeti
- Calvery Mater Hospital Newcastle, Waratah, New South Wales, Australia
| | - Mark Smith
- Haematology, Canterbury District Health Board, Christchurch, Auckland, New Zealand
| | - Ross Ian Baker
- Perth Blood Institute, Perth, Australia.,Western Australia Centre of Thrombosis and Haemostasis (WACTH), Murdoch University, Perth, Australia
| |
Collapse
|
4
|
Chan CK, Wong RSM, Chan JCM, Chong YK, Au Yeung J, Yung TH. Liver injury associated with the use of health supplement HemoHIM. Hong Kong Med J 2022; 28:413-414. [PMID: 38232970 DOI: 10.12809/hkmj219950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Affiliation(s)
- C K Chan
- Hong Kong Poison Information Centre, United Christian Hospital, Hong Kong
| | - R S M Wong
- Prince of Wales Hospital Poison Treatment Centre, Hong Kong
| | - J C M Chan
- Prince of Wales Hospital Poison Treatment Centre, Hong Kong
| | - Y K Chong
- Hospital Authority Toxicology Reference Laboratory, Hong Kong
| | - J Au Yeung
- Hospital Authority Chief Pharmacist's Office, Hong Kong
| | - T H Yung
- Hospital Authority Chief Pharmacist's Office, Hong Kong
| |
Collapse
|
5
|
Huang SY, Yoon SS, Shimizu K, Chng WJ, Chang CS, Wong RSM, Gao S, Wang Y, Gordon SW, Glennane A, Min CK. Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis. Adv Ther 2020; 37:3404-3416. [PMID: 32524500 PMCID: PMC7467415 DOI: 10.1007/s12325-020-01395-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Indexed: 11/25/2022]
Abstract
Introduction The primary analysis of a global phase 3 study that evaluated the efficacy and safety of denosumab versus zoledronic acid for preventing skeletal-related events (SREs) in adults with newly diagnosed multiple myeloma (MM) indicated that denosumab was noninferior to zoledronic acid for time to first on-study SREs. Here we present a subgroup analysis to evaluate efficacy and safety in Asian patients. Methods Patients were randomized 1:1 to receive denosumab 120 mg subcutaneously or zoledronic acid intravenously 4 mg every 4 weeks in a double-blind, double-dummy fashion. All patients received standard-of-care first-line antimyeloma treatment. Each patient received either study drug until an estimated 676 patients experienced at least one on-study SRE and the primary efficacy and safety analyses were completed. Results Of 1718 total enrolled patients, 196 Asian patients (denosumab, n = 103; zoledronic acid, n = 93) were included in this subgroup analysis. Fewer patients in the denosumab group developed first on-study SRE compared with the zoledronic acid group; the crude incidence of SREs at the primary analysis cutoff was 38.8% and 50.5%, respectively (HR [95% CI], 0.77 [0.48–1.26]). All 194 patients receiving at least one dose of study drug experienced at least one treatment-emergent AE. The most common AEs reported in either group (denosumab, zoledronic acid) were diarrhea (51.0%, 51.1%), nausea (42.2%, 46.7%), and pyrexia (38.2%, 41.3%). Treatment-emergent renal toxicity occurred in 9/102 (8.8%) and 20/92 (21.7%) patients, respectively. Similar rates of positively adjudicated osteonecrosis of the jaw (7 [6.9%] vs 5 [5.4%]) and treatment-emergent hypocalcemia (19 [18.6%] vs 17 [18.5%]) were reported in the denosumab and zoledronic acid groups, respectively. Conclusion Efficacy and safety outcomes from this Asian subgroup were comparable to those of the full study population. Overall, this analysis supports denosumab as an additional treatment option for standard of care for Asian patients with newly diagnosed MM with lytic bone lesions. Clinical Trial Registration ClinicalTrials.gov NCT01345019.
Collapse
|
6
|
Mullane KM, Morrison VA, Camacho LH, Arvin A, McNeil SA, Durrand J, Campbell B, Su SC, Chan ISF, Parrino J, Kaplan SS, Popmihajlov Z, Annunziato PW, Cerana S, Dictar MO, Bonvehi P, Tregnaghi JP, Fein L, Ashley D, Singh M, Hayes T, Playford G, Morrissey O, Thaler J, Kuehr T, Greil R, Pecherstorfer M, Duck L, Van Eygen K, Aoun M, De Prijck B, Franke FA, Barrios CHE, Mendes AVA, Serrano SV, Garcia RF, Moore F, Camargo JFC, Pires LA, Alves RS, Radinov A, Oreshkov K, Minchev V, Hubenova AI, Koynova T, Ivanov I, Rabotilova B, Minchev V, Petrov PA, Chilingirov P, Karanikolov S, Raynov J, Grimard D, McNeil S, Kumar D, Larratt LM, Weiss K, Delage R, Diaz-Mitoma FJ, Cano PO, Couture F, Carvajal P, Yepes A, Torres Ulloa R, Fardella P, Caglevic C, Rojas C, Orellana E, Gonzalez P, Acevedo A, Galvez KM, Gonzalez ME, Franco S, Restrepo JG, Rojas CA, Bonilla C, Florez LE, Ospina AV, Manneh R, Zorica R, Vrdoljak DV, Samarzija M, Petruzelka L, Vydra J, Mayer J, Cibula D, Prausova J, Paulson G, Ontaneda M, Palk K, Vahlberg A, Rooneem R, Galtier F, Postil D, Lucht F, Laine F, Launay O, Laurichesse H, Duval X, Cornely OA, Camerer B, Panse J, Zaiss M, Derigs HG, Menzel H, Verbeek M, Georgoulias V, Mavroudis D, Anagnostopoulos A, Terpos E, Cortes D, Umanzor J, Bejarano S, Galeano RW, Wong RSM, Hui P, Pedrazzoli P, Ruggeri L, Aversa F, Bosi A, Gentile G, Rambaldi A, Contu A, Marei L, Abbadi A, Hayajneh W, Kattan J, Farhat F, Chahine G, Rutkauskiene J, Marfil Rivera LJ, Lopez Chuken YA, Franco Villarreal H, Lopez Hernandez J, Blacklock H, Lopez RI, Alvarez R, Gomez AM, Quintana TS, Moreno Larrea MDC, Zorrilla SJ, Alarcon E, Samanez FCA, Caguioa PB, Tiangco BJ, Mora EM, Betancourt-Garcia RD, Hallman-Navarro D, Feliciano-Lopez LJ, Velez-Cortes HA, Cabanillas F, Ganea DE, Ciuleanu TE, Ghizdavescu DG, Miron L, Cebotaru CL, Cainap CI, Anghel R, Dvorkin MV, Gladkov OA, Fadeeva NV, Kuzmin AA, Lipatov ON, Zbarskaya II, Akhmetzyanov FS, Litvinov IV, Afanasyev BV, Cherenkova M, Lioznov D, Lisukov IA, Smirnova YA, Kolomietz S, Halawani H, Goh YT, Drgona L, Chudej J, Matejkova M, Reckova M, Rapoport BL, Szpak WM, Malan DR, Jonas N, Jung CW, Lee DG, Yoon SS, Lopez Jimenez J, Duran Martinez I, Rodriguez Moreno JF, Solano Vercet C, de la Camara R, Batlle Massana M, Yeh SP, Chen CY, Chou HH, Tsai CM, Chiu CH, Siritanaratkul N, Norasetthada L, Sriuranpong V, Seetalarom K, Akan H, Dane F, Ozcan MA, Ozsan GH, Kalayoglu Besisik SF, Cagatay A, Yalcin S, Peniket A, Mullan SR, Dakhil KM, Sivarajan K, Suh JJG, Sehgal A, Marquez F, Gomez EG, Mullane MR, Skinner WL, Behrens RJ, Trevarthe DR, Mazurczak MA, Lambiase EA, Vidal CA, Anac SY, Rodrigues GA, Baltz B, Boccia R, Wertheim MS, Holladay CS, Zenk D, Fusselman W, Wade III JL, Jaslowsk AJ, Keegan J, Robinson MO, Go RS, Farnen J, Amin B, Jurgens D, Risi GF, Beatty PG, Naqvi T, Parshad S, Hansen VL, Ahmed M, Steen PD, Badarinath S, Dekker A, Scouros MA, Young DE, Graydon Harker W, Kendall SD, Citron ML, Chedid S, Posada JG, Gupta MK, Rafiyath S, Buechler-Price J, Sreenivasappa S, Chay CH, Burke JM, Young SE, Mahmood A, Kugler JW, Gerstner G, Fuloria J, Belman ND, Geller R, Nieva J, Whittenberger BP, Wong BMY, Cescon TP, Abesada-Terk G, Guarino MJ, Zweibach A, Ibrahim EN, Takahashi G, Garrison MA, Mowat RB, Choi BS, Oliff IA, Singh J, Guter KA, Ayrons K, Rowland KM, Noga SJ, Rao SB, Columbie A, Nualart MT, Cecchi GR, Campos LT, Mohebtash M, Flores MR, Rothstein-Rubin R, O'Connor BM, Soori G, Knapp M, Miranda FG, Goodgame BW, Kassem M, Belani R, Sharma S, Ortiz T, Sonneborn HL, Markowitz AB, Wilbur D, Meiri E, Koo VS, Jhangiani HS, Wong L, Sanani S, Lawrence SJ, Jones CM, Murray C, Papageorgiou C, Gurtler JS, Ascensao JL, Seetalarom K, Venigalla ML, D'Andrea M, De Las Casas C, Haile DJ, Qazi FU, Santander JL, Thomas MR, Rao VP, Craig M, Garg RJ, Robles R, Lyons RM, Stegemoller RK, Goel S, Garg S, Lowry P, Lynch C, Lash B, Repka T, Baker J, Goueli BS, Campbell TC, Van Echo DA, Lee YJ, Reyes EA, Senecal FM, Donnelly G, Byeff P, Weiss R, Reid T, Roeland E, Goel A, Prow DM, Brandt DS, Kaplan HG, Payne JE, Boeckh MG, Rosen PJ, Mena RR, Khan R, Betts RF, Sharp SA, Morrison VA, Fitz-Patrick D, Congdon J, Erickson N, Abbasi R, Henderson S, Mehdi A, Wos EJ, Rehmus E, Beltzer L, Tamayo RA, Mahmood T, Reboli AC, Moore A, Brown JM, Cruz J, Quick DP, Potz JL, Kotz KW, Hutchins M, Chowhan NM, Devabhaktuni YD, Braly P, Berenguer RA, Shambaugh SC, O'Rourke TJ, Conkright WA, Winkler CF, Addo FEK, Duic JP, High KP, Kutner ME, Collins R, Carrizosa DR, Perry DJ, Kailath E, Rosen N, Sotolongo R, Shoham S, Chen T. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. The Lancet Infectious Diseases 2019; 19:1001-1012. [DOI: 10.1016/s1473-3099(19)30310-x] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Revised: 05/02/2019] [Accepted: 05/03/2019] [Indexed: 12/25/2022]
|
7
|
Dunkley S, Lam JCM, John MJ, Wong RSM, Tran H, Yang R, Nair SC, Shima M, Street A, Srivastava A. Principles of haemophilia care: The asia pacific perspective. Response. Haemophilia 2018; 24:e243-e244. [PMID: 29901827 DOI: 10.1111/hae.13522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/28/2018] [Indexed: 12/01/2022]
Affiliation(s)
- S Dunkley
- Haemophilia Treatment Centre, Royal Prince Alfred Hospital, Sydney, Australia
| | - J C M Lam
- Department of Paediatric Subspecialties, KK Women's and Children's Hospital, Singapore, Singapore
| | - M J John
- Department of Clinical Haematology, Christian Medical College, Ludhiana, India
| | - R S M Wong
- Department of Medicine & Therapeutics and Sir Y.K. Pao Centre for Cancer, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - H Tran
- Ronald Sawers Haemophilia Centre, The Alfred Hospital Melbourne, Melbourne, VIC, Australia
| | - R Yang
- State Key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
| | - S C Nair
- Department of Immunohematology & Transfusion Medicine, Christian Medical College, Vellore, India
| | - M Shima
- Department of Paediatrics, Nara Medical University, Kashihara, Nara, Japan
| | - A Street
- Department of Immunology and Pathology, Monash University, Melbourne, VIC, Australia
| | - A Srivastava
- Department of Hematology, Christian Medical College, Vellore, India
| |
Collapse
|
8
|
Lam PL, Lee KKH, Wong RSM, Cheng GYM, Bian ZX, Chui CH, Gambari R. Recent advances on topical antimicrobials for skin and soft tissue infections and their safety concerns. Crit Rev Microbiol 2018; 44:40-78. [PMID: 28423970 DOI: 10.1080/1040841x.2017.1313811] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Antimicrobial resistance of disease-related microorganisms is considered a worldwide prevalent and serious issue which increases the failure of treatment outcomes and leads to high mortality. Considering that the increased resistance to systemic antimicrobial therapy often needs of the use of more toxic agents, topical antimicrobial therapy emerges as an attractive route for the treatment of infectious diseases. The topical antimicrobial therapy is based on the absorption of high drug doses in a readily accessible skin surface, resulting in a reduction of microbial proliferation at infected skin sites. Topical antimicrobials retain the following features: (a) they are able to escape the enzymatic degradation and rapid clearance in the gastrointestinal tract or the first-pass metabolism during oral administration; (b) alleviate the physical discomfort related to intravenous injection; (c) reduce possible adverse effects and drug interactions of systemic administrations; (d) increase patient compliance and convenience; and (e) reduce the treatment costs. Novel antimicrobials for topical application have been widely exploited to control the emergence of drug-resistant microorganisms. This review provides a description of antimicrobial resistance, common microorganisms causing skin and soft tissue infections, topical delivery route of antimicrobials, safety concerns of topical antimicrobials, recent advances, challenges and future prospective in topical antimicrobial development.
Collapse
Affiliation(s)
- P L Lam
- a Department of Applied Biology and Chemical Technology, State Key Laboratory of Chirosciences , The Hong Kong Polytechnic University , Hong Kong , P.R. China
| | - K K H Lee
- b Department of Medicine and Therapeutics, School of Biomedical Sciences, MOE Key Laboratory for Regenerative Medicine , The Chinese University of Hong Kong , Hong Kong , P.R. China
| | - R S M Wong
- b Department of Medicine and Therapeutics, School of Biomedical Sciences, MOE Key Laboratory for Regenerative Medicine , The Chinese University of Hong Kong , Hong Kong , P.R. China
| | - G Y M Cheng
- c Faculty of Health Sciences , University of Macau , Macau , P.R. China
| | - Z X Bian
- d Clinical Division, School of Chinese Medicine , Hong Kong Baptist University , Hong Kong , P.R. China
| | - C H Chui
- a Department of Applied Biology and Chemical Technology, State Key Laboratory of Chirosciences , The Hong Kong Polytechnic University , Hong Kong , P.R. China
- d Clinical Division, School of Chinese Medicine , Hong Kong Baptist University , Hong Kong , P.R. China
| | - R Gambari
- e Department of Life Sciences and Biotechnology, Centre of Biotechnology , University of Ferrara , Ferrara , Italy
| |
Collapse
|
9
|
Lam PL, Lee KKH, Wong RSM, Cheng GYM, Cheng SY, Yuen MCW, Lam KH, Gambari R, Kok SHL, Chui CH. Corrigendum to “Development of hydrocortisone succinic acid/and 5-fluorouracil/chitosan microcapsules for oral and topical drug deliveries” [Bioorg. Med. Chem. Lett. 22 (2012) 3213–3218]. Bioorg Med Chem Lett 2014; 24:4607. [DOI: 10.1016/j.bmcl.2014.07.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
10
|
Lam KH, Lee KKH, Gambari R, Kok SHL, Kok TW, Chan ASC, Bian ZX, Wong WY, Wong RSM, Lau FY, Tong SW, Chan KW, Cheng CH, Chui CH, Tang JCO. Anti-tumour and pharmacokinetics study of 2-Formyl-8-hydroxy-quinolinium chloride as Galipea longiflora alkaloid analogue. Phytomedicine 2014; 21:877-882. [PMID: 24680618 DOI: 10.1016/j.phymed.2014.02.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/15/2013] [Revised: 12/10/2013] [Accepted: 02/22/2014] [Indexed: 06/03/2023]
Abstract
The quinolinium chloride salt of 8-hydroxyqinolinecarbaldehyde (2-Formyl-8-hydroxy-quinolinium chloride) was prepared as Galipea longiflora alkaloid analogue and its anticancer activity was evaluated both in vitro and in vivo. This chloride salt was found to show certain degree of selectivity between hepatoma cells and normal hepatocytes in vitro. Athymic nude mice Hep3B xenograft model further demonstrated that this 2-Formyl-8-hydroxy-quinolinium chloride could execute strong anti-tumour activity with the identification of extensive necrotic feature from the tumour xenograft and limited adverse toxicological effect.
Collapse
Affiliation(s)
- Kim-Hung Lam
- State Key Laboratory of Chirosciences, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, People's Republic of China.
| | - Kenneth Ka-Ho Lee
- School of Biomedical Sciences and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, People's Republic of China
| | - Roberto Gambari
- Centre of Biotechnology, Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy
| | - Stanton Hon-Lung Kok
- School of Biomedical Sciences and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, People's Republic of China
| | - Tsz-Wai Kok
- School of Biomedical Sciences and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, People's Republic of China
| | - Albert Sun-Chi Chan
- Institute of Creativity, Department of Chemistry and Institute of Advanced Materials, Hong Kong Baptist University, Waterloo Road, Kowloon Tong, Hong Kong, People's Republic of China; Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Waterloo Road, Kowloon Tong, Hong Kong, People's Republic of China
| | - Zhao-Xiang Bian
- Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Waterloo Road, Kowloon Tong, Hong Kong, People's Republic of China
| | - Wai-Yeung Wong
- Institute of Creativity, Department of Chemistry and Institute of Advanced Materials, Hong Kong Baptist University, Waterloo Road, Kowloon Tong, Hong Kong, People's Republic of China
| | - Raymond Siu-Ming Wong
- School of Biomedical Sciences and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, People's Republic of China
| | - Fung-Yi Lau
- School of Biomedical Sciences and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, People's Republic of China
| | - See-Wai Tong
- School of Biomedical Sciences and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, People's Republic of China
| | - Kit-Wah Chan
- School of Biomedical Sciences and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, People's Republic of China
| | - Chor-Hing Cheng
- State Key Laboratory of Chirosciences, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, People's Republic of China
| | - Chung-Hin Chui
- State Key Laboratory of Chirosciences, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, People's Republic of China; School of Biomedical Sciences and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, People's Republic of China; Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Waterloo Road, Kowloon Tong, Hong Kong, People's Republic of China.
| | - Johnny Cheuk-On Tang
- State Key Laboratory of Chirosciences, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, People's Republic of China.
| |
Collapse
|
11
|
Lam KH, Gambari R, Lee KKH, Chen YX, Kok SHL, Wong RSM, Lau FY, Cheng CH, Wong WY, Bian ZX, Chan ASC, Tang JCO, Chui CH. Preparation of 8-hydroxyquinoline derivatives as potential antibiotics against Staphylococcus aureus. Bioorg Med Chem Lett 2013; 24:367-70. [PMID: 24269165 DOI: 10.1016/j.bmcl.2013.10.072] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2013] [Revised: 10/28/2013] [Accepted: 10/31/2013] [Indexed: 10/26/2022]
Abstract
This work describes the preparation of quinoline compounds as possible anti-bacterial agents. The synthesized quinoline derivatives show anti-bacterial activity towards Staphylococcus aureus. It is interesting to observe that the synthetic 5,7-dibromo-2-methylquinolin-8-ol (4) shows a similar minimum inhibitory concentration of 6.25μg/mL as compared to that of methicillin (3.125μg/mL) against Staphylococcus aureus.
Collapse
Affiliation(s)
- Kim-Hung Lam
- State Key Laboratory of Chirosciences, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China.
| | - Roberto Gambari
- Centre of Biotechnology, Department of Life Sciences and Biotechnology, The University of Ferrara, Ferrara, Italy
| | - Kenneth Ka-Ho Lee
- School of Biomedical Sciences and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
| | - Yi-Xin Chen
- Department of Chemistry, Guangzhou University, Guangzhou, People's Republic of China
| | - Stanton Hon-Lung Kok
- School of Biomedical Sciences and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
| | - Raymond Siu-Ming Wong
- School of Biomedical Sciences and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
| | - Fung-Yi Lau
- School of Biomedical Sciences and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
| | - Chor-Hing Cheng
- State Key Laboratory of Chirosciences, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China
| | - Wai-Yeung Wong
- Institute of Creativity, Department of Chemistry and Institute of Advanced Materials, Hong Kong Baptist University, Waterloo Road, Kowloon Tong, Hong Kong, China
| | - Zhao-Xiang Bian
- Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Waterloo Road, Kowloon Tong, Hong Kong, China
| | - Albert Sun-Chi Chan
- Institute of Creativity, Department of Chemistry and Institute of Advanced Materials, Hong Kong Baptist University, Waterloo Road, Kowloon Tong, Hong Kong, China; Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Waterloo Road, Kowloon Tong, Hong Kong, China
| | - Johnny Cheuk-On Tang
- State Key Laboratory of Chirosciences, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China.
| | - Chung-Hin Chui
- State Key Laboratory of Chirosciences, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China; School of Biomedical Sciences and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China; Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Waterloo Road, Kowloon Tong, Hong Kong, China.
| |
Collapse
|
12
|
Zhao Z, Gambari R, Lee KKH, Kok SHL, Wong RSM, Lau FY, Tang JCO, Lam KH, Cheng CH, Hau DKP, Chui CH, Wong WY, Wong WK. In vivo antitumour activity of amphiphilic silicon(IV) phthalocyanine with axially ligated rhodamine B. Bioorg Med Chem Lett 2013; 23:2373-6. [PMID: 23473678 DOI: 10.1016/j.bmcl.2013.02.049] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2013] [Revised: 02/04/2013] [Accepted: 02/09/2013] [Indexed: 11/18/2022]
Abstract
We explore the possible cellular cytotoxic activity of an amphiphilic silicon(IV) phthalocyanine with axially ligated rhodamine B under ambient light experimental environment as well as its in vivo antitumour potential using Hep3B hepatoma cell model. After loading into the Hep3B hepatoma cells, induction of cellular cytotoxicity and cell cycle arrest were detected. Strong growth inhibition of tumour xenograft together with significant tumour necrosis and limited toxicological effects exerted on the nude mice could be identified.
Collapse
Affiliation(s)
- Zhinxin Zhao
- Institute of Creativity, Department of Chemistry and Institute of Advanced Materials, Hong Kong Baptist University, Waterloo Road, Kowloon Tong, Hong Kong, China
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Lam KH, Lee KKH, Gambari R, Wong RSM, Cheng GYM, Tong SW, Chan KW, Lau FY, Lai PBS, Wong WY, Chan ASC, Kok SHL, Tang JCO, Chui CH. Preparation of Galipea officinalis Hancock type tetrahydroquinoline alkaloid analogues as anti-tumour agents. Phytomedicine 2013; 20:166-171. [PMID: 23123223 DOI: 10.1016/j.phymed.2012.09.026] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/07/2012] [Revised: 07/31/2012] [Accepted: 09/14/2012] [Indexed: 06/01/2023]
Abstract
The preparation of chiral tetrahydroquinolines using Ir-catalysed asymmetric hydrogenation and their possible cytotoxic potential anti-cancer activity were reported. Both of the in vitro cytotoxicity assay on a series of human cancer cell lines including A549 small cell lung cancer, MDA-MB-231 breast cancer, SaoS2 sacroma, SKHep-1 hepatoma and Hep3B hepatocellular carcinoma as well as in vivo animal model using Hep3B hepatocellular tumour xenograft on athymic nude mice suggest that 1,2,3,4-tetrahydroquin-8-ol is a potential anti-tumour alkaloid which may be further developed as a novel cancer chemotherapeutic agent.
Collapse
Affiliation(s)
- Kim-Hung Lam
- Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic University, Hung Hom, Hong Kong, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Lam PL, Kok SHL, Ho YW, Wong RSM, Cheng GYM, Cheng CH, Lam KH, Gambari R, Lee KKH, Chui CH. A novel green gelatin–agar microencapsulation system with P. urinaria as an improved anti-A. niger model. Carbohydr Polym 2013; 92:877-80. [DOI: 10.1016/j.carbpol.2012.09.080] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2012] [Revised: 09/23/2012] [Accepted: 09/27/2012] [Indexed: 10/27/2022]
|
15
|
Lam PL, Lee KKH, Wong RSM, Cheng GYM, Cheng SY, Yuen MCW, Lam KH, Gambari R, Kok SHL, Chui CH. Development of hydrocortisone succinic acid/and 5-fluorouracil/chitosan microcapsules for oral and topical drug deliveries. Bioorg Med Chem Lett 2012; 22:3213-8. [DOI: 10.1016/j.bmcl.2012.03.031] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2012] [Revised: 02/26/2012] [Accepted: 03/07/2012] [Indexed: 11/29/2022]
|
16
|
Lam PL, Gambari R, Yip J, Yuen MCW, Lam KH, Wong RSM, Wang XW, Tang JCO, Kok SHL, Chui CH. Development of phyllanthin containing microcapsules and their improved biological activity towards skin cells and Staphylococcus aureus. Bioorg Med Chem Lett 2012; 22:468-71. [DOI: 10.1016/j.bmcl.2011.10.097] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2011] [Revised: 10/17/2011] [Accepted: 10/28/2011] [Indexed: 10/15/2022]
|
17
|
Li L, Chow WC, Wong WY, Chui CH, Wong RSM. Synthesis, characterization and photovoltaic behavior of platinum acetylide polymers with electron-deficient 9,10-anthraquinone moiety. J Organomet Chem 2011. [DOI: 10.1016/j.jorganchem.2010.08.044] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
18
|
Hau DKP, Zhu GY, Leung AKM, Wong RSM, Cheng GYM, Lai PBS, Tong SW, Lau FY, Chan KW, Wong WY, Lam KH, Cheng CH, Cheung F, Chui CH, Gambari R, Fong DWF. In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma. Phytomedicine 2010; 18:11-15. [PMID: 21036022 DOI: 10.1016/j.phymed.2010.09.001] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/21/2010] [Revised: 07/19/2010] [Accepted: 09/04/2010] [Indexed: 05/30/2023]
Abstract
We have investigated the potential in vivo anti-tumour activity of corilagin using the Hep3B hepatocellular carcinoma cell line and an athymic nude mice xenograft model. The purity of corilagin was confirmed by high performance liquid chromatographic analysis. Corilagin was administrated intraperitoneally for a continuous period of 7 days at a concentration of 15 mg/kg of body weight per day. A significant inhibition of tumour growth was observed when treated mice are compared with control groups. Furthermore, analysis of enzymes markers of liver function, including alanine aminotransferase and asparate aminotransferase, suggested that current therapeutic dosage of corilagin did not exert adverse effect on liver. Our observations support the view that corilagin is considerably effective to retard the in vivo growth of xenografted Hep3B hepatocellular carcinoma.
Collapse
Affiliation(s)
- Desmond Kwok-Po Hau
- Research and Development Division, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Lam KH, Chui CH, Gambari R, Wong RSM, Cheng GYM, Lau FY, Lai PBS, Tong SW, Chan KW, Wong WY, Chan ASC, Tang JCO. The preparation of bi-functional organophosphine oxides as potential antitumor agents. Eur J Med Chem 2010; 45:5527-30. [DOI: 10.1016/j.ejmech.2010.08.038] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2010] [Revised: 08/03/2010] [Accepted: 08/13/2010] [Indexed: 11/16/2022]
|
20
|
Cheng SY, Yuen MCW, Lam PL, Gambari R, Wong RSM, Cheng GYM, Lai PBS, Tong SW, Chan KW, Lau FY, Kok SHL, Lam KH, Chui CH. Synthesis, characterization and preliminary analysis of in vivo biological activity of chitosan/celecoxib microcapsules. Bioorg Med Chem Lett 2010; 20:4147-51. [DOI: 10.1016/j.bmcl.2010.05.054] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2010] [Revised: 05/13/2010] [Accepted: 05/14/2010] [Indexed: 11/30/2022]
|
21
|
Wang Q, Yuen MCW, Lu GL, Ho CL, Zhou GJ, Keung OM, Lam KH, Gambari R, Tao XM, Wong RSM, Tong SW, Chan KW, Lau FY, Cheung F, Cheng GYM, Chui CH, Wong WY. Synthesis of 9,9-Dialkyl-4,5-diazafluorene Derivatives and Their Structure-Activity Relationships Toward Human Carcinoma Cell Lines. ChemMedChem 2010; 5:559-66. [DOI: 10.1002/cmdc.201000034] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
22
|
Hau DKP, Wong RSM, Cheng GYM, Wong WY, Tong SW, Chan KW, Leung AKM, Zhu GY, Lai PBS, Lau FY, Chui CH, Gambari R, Fong DWF. Novel Use of Silymarin as Delayed Therapy for Acetaminophen-Induced Acute Hepatic Injury. ACTA ACUST UNITED AC 2010; 17:209-13. [DOI: 10.1159/000319317] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
23
|
Chui CH, Wong RSM, Gambari R, Cheng GYM, Yuen MCW, Chan KW, Tong SW, Lau FY, Lai PBS, Lam KH, Ho CL, Kan CW, Leung KSY, Wong WY. Antitumor activity of diethynylfluorene derivatives of gold(I). Bioorg Med Chem 2009; 17:7872-7. [DOI: 10.1016/j.bmc.2009.10.034] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2009] [Revised: 10/15/2009] [Accepted: 10/15/2009] [Indexed: 10/20/2022]
|
24
|
You JHS, Tsui KKN, Wong RSM, Cheng G. Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy. Clin Pharmacol Ther 2009; 86:540-7. [DOI: 10.1038/clpt.2009.104] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
25
|
Lu GL, Ho CL, Wang Q, Wong WY, Chui CH, Wong RSM, Gambari R, Lau FY, Yuen MCW, Tong CSW, Chan AKW, Tang JCO, Ho KP, Cheng GYM. Synthesis and Characterization of Some Metal Complexes of 4,5-Diazafluoren-9-one and their Biological Effects on Human Carcinoma Cells. Aust J Chem 2008. [DOI: 10.1071/ch08342] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Three new transition metal complexes of 4,5-diazafluoren-9-one, [(DAFO)PdCl2], [(DAFO)PtCl2], and [(DAFO)ZnCl2], were prepared in good yields by the reactions between appropriate metal chloride precursors and 4,5-diazafluoren-9-one under ambient conditions. The structures of these metal complexes were established by spectroscopic (Fourier-transform IR, NMR, and fast-atom bombardment mass spectrometry) techniques. The possible biological activity of these compounds on three human cancer cell lines including Hep3B, MDAMB-231, and SKHep-1 was investigated. The results obtained showed that both zinc- and platinum-containing compounds exhibit a similar growth inhibitory effect on these three cancer cell lines when compared with the prototypical cis-platin. In contrast, the corresponding palladium congener is virtually biologically inactive in these trials.
Collapse
|
26
|
You JHS, Chan FWH, Wong RSM, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005; 59:582-7. [PMID: 15842557 PMCID: PMC1884850 DOI: 10.1111/j.1365-2125.2005.02361.x] [Citation(s) in RCA: 98] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2004] [Indexed: 11/29/2022] Open
Abstract
AIM To examine the optimal range of International Normalized Ratio (INR) for Chinese patients receiving warfarin for moderate-intensity anticoagulation. METHODS This was a retrospective cohort study conducted at the ambulatory setting of a 1400-bed public teaching hospital in Hong Kong. The INR measurements and occurrence of serious or life-threatening haemorrhagic and thromboembolic events among patients newly started on warfarin from 1 January 1999 to 30 June 2001 for indications with target INR 2-3 were analysed. The INR-specific incidence of bleeding and thromboembolism were calculated. RESULTS A total of 491 patients were included, contributing to 453 patient-years of observation period. Forty-seven of the 491 patients experienced 25 haemorrhagic events (5.5 per 100 patient-years) and 27 thromboembolic events (6.0 per 100 patient-years). The percentage of patient-time spent within therapeutic INR range (2-3), INR <2 and INR >3 were 50, 44 and 6%, respectively. The incidence of either haemorrhagic or thromboembolic events was lowest (< or =4 events per 100 patient-years) at INR values between 1.8 and 2.4. CONCLUSIONS An INR of 1.8-2.4 appeared to be associated with the lowest incidence rate of major bleeding or thromboembolic events in a cohort of Hong Kong Chinese patients receiving warfarin therapy for moderate-intensity anticoagulation.
Collapse
Affiliation(s)
- J H S You
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.
| | | | | | | |
Collapse
|
27
|
Chow LMC, Tang JCO, Teo ITN, Chui CH, Lau FY, Leung TWT, Cheng G, Wong RSM, Wong ILK, Tsang KMS, Tan WQ, Zhao YZ, Lai KB, Lam WH, Guo DA, Chan ASC. Antiproliferative activity of the extract of Gleditsia sinensis fruit on human solid tumour cell lines. Chemotherapy 2004; 48:303-8. [PMID: 12673105 DOI: 10.1159/000069713] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND The fruit extract of Gleditsia sinensis Lam. (GSE) is a traditional herbal medicine that is saponin-rich. However, its activity on solid tumour cell lines has never been demonstrated. METHODS The activity of GSE was demonstrated in four cancer cell lines (breast cancer MCF-7, MDA-MB231, hepatoblastoma HepG2 and oesophageal squamous carcinoma cell line SLMT-1) using MTT assay, anchorage-independent clonogenicity assay, DNA laddering and in situ cell death detection. RESULTS The mean MTT(50) (the mean concentration of GSE to reduce MTT activity by 50%) ranged from 16 to 20 microg/ml of GSE. An anchorage-independent clonogenicity assay showed that all of the four solid tumour cell lines gradually lost their regeneration potential after treatment with GSE, DNA fragmentation and TUNEL analysis demonstrated that the action of GSE is both dose- and time course-dependent. CONCLUSIONS Our results suggest that GSE has a cytotoxic activity and can induce apoptosis in human solid tumour cell lines.
Collapse
Affiliation(s)
- L M C Chow
- Department of Applied Biology and Chemical Technology and Central Laboratory of the Institute of Molecular Technology for Drug Discovery and Synthesis, Hong Kong Polytechnic University, China.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Wong RSM. Severe acute respiratory syndrome in a doctor working at the Prince of Wales Hospital. Hong Kong Med J 2003; 9:202-5. [PMID: 12777657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2023] Open
Abstract
Severe acute respiratory syndrome is a new disease that is highly contagious and is spreading in the local community and worldwide. This report is of a hospital medical officer with severe acute respiratory syndrome. He presented with sudden onset of fever, chills, myalgia, headache, and dizziness in early March 2003. He developed progressive respiratory symptoms and bilateral pulmonary infiltrates during the second week of his illness. Blood tests showed lymphopenia, mild thrombocytopenia, and prolonged activated partial thromboplastin time with normal d-dimer level. His chest condition gradually responded to ribavirin and corticosteroids, and serial chest X-ray showed resolving pulmonary infiltrates. The importance of early diagnosis lies in the potential for early treatment, leading to better response.
Collapse
Affiliation(s)
- R S M Wong
- Department of Medicine and Therapeutics, The Chinese University of Hong Kongg, Prince of Wales Hospital, Shatin, Hong Kong
| |
Collapse
|
29
|
Chow KM, Wong RSM, Cheng G. D-dimer test in deep vein thrombosis. J Intern Med 2002; 252:575; author reply 576. [PMID: 12472920 DOI: 10.1046/j.1365-2796.2002.01072.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
30
|
|